

7. Ahmad T, Voora D, Becker RC. The pharmacogenomics of antiplatelet agents: towards personalized therapy. *Nat Rev Cardiol* 2011;8:560-71.
8. Breet NJ, van Werkum JW, Bouman HJ et al. Comparison of platelet function tests in predicting outcome in patients undergoing coronary stent implantation. *JAMA* 2010;303:754-62.
9. Bonello L, Tantry US, Marcucci R et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. *J Am Coll Cardiol* 2010;56:919-33.
10. Schuldinger AR, O'Connell JR, Bliden KP et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. *JAMA* 2009;302:849-57.
11. Mega JL, Simon T, Collet JP et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI. *JAMA* 2010;304:1821-30.
12. Hulot JS, Collet JP, Silvain J et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19\*2 loss-of-function allele or proton pump inhibitor coadministration. *J Am Coll Cardiol* 2010;56:134-43.
13. Price MJ, Berger PB, Teirstein PS et al. Standard- vs. high-dose clopidogrel based on testing after percutaneous coronary intervention. *JAMA* 2011;305:1097-106.
14. Mega JL, Close SL, Wiviott SD et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. *Lancet* 2010;376:1312-9.
15. Wallentin L, James S, Storey RF et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. *Lancet* 2010;376:1320-8.
16. Scott SA, Sangkuhl K, Gardner EE et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. *Clin Pharmacol Ther* 2011; 90:328-32.
17. Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. *J Clin Invest* 2004;113:240-5.
18. Damman P, Woudstra P, Kuijt WJ et al. P2Y12 inhibition in clinical practice. *J Thromb Thrombolysis* 2012;33:143-53.
19. Kazui M, Nishiyama Y, Ishizuka T et al. Identification of the human cytochrome p450 enzymes involved in the two oxidative steps in the bioactivation of clopi-
- dogrel to its pharmacologically active metabolite. *Drug Metab Dispos* 2010;38:92-9.
20. Luo M, Li J, Xu X et al. ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: an meta-analysis. *Thromb Res* 2012;129:754-9.
21. Bouman HJ, Schöning E, van Werkum JW et al. Paroxonase-1 is a major determinant of clopidogrel efficacy. *Nature Med* 2011;17:110-6.
22. Reny JL, Combescure C, Deali Y et al, for the PON1 meta-analysis group. Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis. *J Thromb Haemost* 21. apr 2012 (epub ahead of print).
23. Hulot JS, Bura A, Villard E et al. Cytochrome p450 2c19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. *Blood* 2006;108:2044-7.
24. Kim KA, Park PW, Hong SJ et al. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. *Clin Pharmacol Ther* 2008;84:236-42.
25. Sim SC, Risinger C, Dahl M et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. *Clin Pharmacol Ther* 2006;79:103-13.
26. Sibbing D, Koch W, Gebhard D et al. Cytochrome 2C19\*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. *Circulation* 2010;121:512-8.
27. Holmes MV, Perel P, Shah T et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events. *JAMA* 2011;306:2704-14.
28. Bhatt DL, Eikelboom JW, Simonsen KL et al. The relationship between CYP2C19 genotypes and polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. *Eur Heart J* 22. mar 2012 (epub ahead of print).
29. Holmes DR, Dehmer GJ, Kaul S et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA 'boxed warning'. *Circulation* 2010;122:537-57.
30. Roberts JD, Wells GA, Le May MR et al. Point-of-care genetic testing for personalization of antiplatelet treatment (RAPID GENE): a prospective, randomized, proof-of-concept trial. *Lancet* 2012;379:1705-11.

## Sundhedsstyrelsen

### TILSKUDET TIL LÆGEMIDLER

Sundhedsstyrelsen meddeler, at der fra 4. marts 2013 ydes generelt uklasuleret tilskud efter sundhedslovens § 144 til følgende lægemidler:

- (H-04-AA-01) GlucaGen Hypokit pulver og solvens til injektion, opløsning\*, Abacus Medicine A/S
- (R-03-AC-18) Hirobriz Breezhaler inhalationspulver\*, Novartis Healthcare A/S
- (G-03-GA-02) Meropur pulver og solvens til injektion, opløsning\*, 2care4 ApS
- (R-03-DC-03) Montelukast »Actavis« tabletter, Actavis A/S
- (R-03-DC-03) Montelukast »Actavis« tyggetabletter, Actavis A/S
- (R-03-DC-03) Montelukast »Aspen« tabletter, Navamedic ASA
- (R-03-DC-03) Montelukast »Aspen« tyggetabletter, Navamedic ASA
- (R-03-DC-03) Montelukast »Krka« tabletter, Krka Sverige AB
- (R-03-DC-03) Montelukast »Krka« tyggetabletter, Krka Sverige AB
- (R-03-DC-03) Montelukast »Orion« tabletter, Orion Pharma A/S
- (R-03-DC-03) Montelukast »Sandoz« tabletter, Sandoz A/S
- (R-03-DC-03) Montelukast »Sandoz« tyggetabletter, Sandoz A/S
- (R-03-DC-03) Montelukast »Stada« tabletter, PharmaCoDane ApS
- (R-03-DC-03) Montelukast »Stada« tyggetabletter, PharmaCoDane ApS
- (R-03-DC-03) Montelukast »Teva« tabletter, Teva Denmark A/S

- (R-03-DC-03) Montelukast »Teva« tyggetabletter, Teva Denmark A/S
- (N-02-CC-02) Naratriptan »A-Pharma« tabletter\*, A-Pharma ApS
- (G-02-CB-04) Norprolac tabletter\*, Paranova Danmark A/S
- (R-01-AB-05) Rhinocort Turbuhaler næsepudder\*, Abacus Medicine A/S
- (R-03-AC-02) Salbutamol »2care4« inhalationsvæske\*, 2care4 ApS
- (G-04-BD-07) Tolterodin »Pfizer« depotkapsler\*, Pfizer ApS
- (J-05-AB-11) Valaciclovir »2care4« tabletter\*, 2care4 ApS
- (N-06-AX-16) Venlafaxin »2care4« depotkapsler\*, 2care4 ApS
- (N-05-AE-04) Ziprasidone »Sandoz« kapsler\*, Sandoz A/S

Der ydes generelt klausuleret tilskud til følgende lægemiddel:

- (N-02-BE-01) Paracetamol »Teva« tabletter\*, Teva Denmark A/S

Lægemidlet er klausuleret til personer, der opfylder følgende sygdomsklausul: Kroniske smerter. En betingelse for at opnå tilskud er, at lægen har skrevet »tilskud« på recepten.

\*) omfattet af tilskudsprissystemet.